| Autor: |
Ghosh, Sudakshina, Gupta, Manveen, Weiling Xu, Mavrakis, Deloris A., Janocha, Allison J., Comhair, Suzy A. A., Haque, Mohammad Mahfuzul, Stuehr, Dennis J., Jun Yu, Polgar, Peter, Prasad, Sathyamangla V. Naga, Erzurum, Serpil C. |
| Předmět: |
|
| Zdroj: |
American Journal of Physiology: Lung Cellular & Molecular Physiology; Jun2016, Vol. 310 Issue 11, pL1199-L1205, 7p |
| Abstrakt: |
The impairment of vasodilator nitric oxide (NO) production is well accepted as a typical marker of endothelial dysfunction in vascular diseases, including in the pathophysiology of pulmonary arterial hypertension (PAH), but the molecular mechanisms accounting for loss of NO production are unknown. We hypothesized that low NO production by pulmonary arterial endothelial cells in PAH is due to inactivation of NO synthase (eNOS) by aberrant phosphorylation of the protein. To test the hypothesis, we evaluated eNOS levels, dimerization, and phosphorylation in the vascular endothelial cells and lungs of patients with PAH compared with controls. In mechanistic studies, eNOS activity in endothelial cells in PAH lungs was found to be inhibited due to phosphorylation at T495. Evidence pointed to greater phosphorylation/activation of protein kinase C (PKC) α and its greater association with eNOS as the source of greater phosphorylation at T495. The presence of greater amounts of pT495-eNOS in plexiform lesions in lungs of patients with PAH confirmed the pathobiological mechanism in vivo. Transfection of the activating mutation of eNOS (T495A/ S1177D) restored NO production in PAH cells. Pharmacological blockade of PKC activity by β-blocker also restored NO formation by PAH cells, identifying one mechanism by which β-blockers may benefit PAH and cardiovascular diseases through recovery of endothelial functions. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
